{"id":"quadrivalent-human-papillomavirus-vaccine","safety":{"commonSideEffects":[{"rate":"83","effect":"Injection site pain"},{"rate":"25","effect":"Injection site swelling"},{"rate":"25","effect":"Injection site erythema"},{"rate":"13","effect":"Fever"},{"rate":"6","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL6068359","moleculeType":"Vaccine component"},"_dailymed":{"setId":"30952400-0572-4431-9150-3a41affffb9a","title":"GARDASIL (HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, AND 18) VACCINE, RECOMBINANT) INJECTION, SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The quadrivalent HPV vaccine contains virus-like particles (VLPs) derived from the major capsid protein of four HPV types. These VLPs are non-infectious but structurally similar to natural HPV virions, triggering a robust humoral immune response that generates neutralizing antibodies. This antibody response provides protection against infection by these HPV types, preventing cervical cancer, genital warts, and other HPV-related malignancies.","oneSentence":"The vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18) to prevent infection and associated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:24:27.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of anal cancer and other HPV-related cancers"}]},"trialDetails":[{"nctId":"NCT07256912","phase":"PHASE4","title":"A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2026-04-01","conditions":"Vaccine Effectiveness, HPV Vaccination, Single Dose","enrollment":1266},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT06632912","phase":"PHASE3","title":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Vaccine and Serum Institute, China","startDate":"2025-11-21","conditions":"Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma","enrollment":1800},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT00092534","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-14","conditions":"Cervical Cancer, Genital Warts","enrollment":12167},{"nctId":"NCT05329961","phase":"EARLY_PHASE1","title":"Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2022-09-26","conditions":"Human Papilloma Virus","enrollment":155},{"nctId":"NCT05266898","phase":"PHASE4","title":"Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2022-11-30","conditions":"Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection","enrollment":250},{"nctId":"NCT06915779","phase":"","title":"Long Term Follow-up of HPV Vaccine in HIV (CTN 236)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-06-01","conditions":"Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus","enrollment":241},{"nctId":"NCT06650956","phase":"NA","title":"Integration to Improve Adolescent Health and HPV Vaccination in Laos","status":"RECRUITING","sponsor":"Health Poverty Action","startDate":"2024-11-01","conditions":"Healthy, Adolescents, Integrated, Community-Health Systems","enrollment":700},{"nctId":"NCT00733122","phase":"PHASE3","title":"Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-01","conditions":"HPV Infections","enrollment":""},{"nctId":"NCT04508309","phase":"PHASE3","title":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-15","conditions":"Cervical Cancer","enrollment":1025},{"nctId":"NCT06281119","phase":"PHASE3","title":"Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-03","conditions":"Human Papillomavirus Infection","enrollment":450},{"nctId":"NCT03493542","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-31","conditions":"Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ","enrollment":766},{"nctId":"NCT00798265","phase":"PHASE1","title":"A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-06-29","conditions":"Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent","enrollment":26},{"nctId":"NCT02653118","phase":"","title":"Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-22","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":4453},{"nctId":"NCT00573651","phase":"NA","title":"Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2007-11","conditions":"Arthritis","enrollment":43},{"nctId":"NCT00501189","phase":"","title":"Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities","status":"WITHDRAWN","sponsor":"Eisenhower Army Medical Center","startDate":"2007-08","conditions":"Papillomavirus Infections","enrollment":""},{"nctId":"NCT04422366","phase":"PHASE3","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2020-04-28","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":8000},{"nctId":"NCT06142461","phase":"PHASE2","title":"Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System","status":"WITHDRAWN","sponsor":"PharmaJet, Inc.","startDate":"2024-05-31","conditions":"Vaccine Reaction","enrollment":""},{"nctId":"NCT02263703","phase":"PHASE3","title":"Immunogenicity of HPV Vaccine in Immunosuppressed Children","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2007-05","conditions":"Autoimmune Disease, Juvenile Idiopathic Arthritis, Inflammatory Bowel Disease","enrollment":55},{"nctId":"NCT05027776","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2021-09-15","conditions":"HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer","enrollment":1348},{"nctId":"NCT05371353","phase":"","title":"Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine","status":"RECRUITING","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2022-05-14","conditions":"HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer","enrollment":600},{"nctId":"NCT06345885","phase":"PHASE4","title":"Immunogenicity and Safety of One Dose of HPV Vaccine","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2023-02-23","conditions":"Human Papillomavirus Vaccines","enrollment":200},{"nctId":"NCT00667563","phase":"PHASE1","title":"Vaccine Therapy in Preventing HPV in HIV-Positive Women in India","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2009-08","conditions":"Cervical Cancer, Nonneoplastic Condition, Precancerous Condition","enrollment":150},{"nctId":"NCT04590521","phase":"PHASE4","title":"HPV Vaccine Immunity in High-risk Women","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-09-14","conditions":"HPV Infection","enrollment":63},{"nctId":"NCT05435209","phase":"PHASE4","title":"Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents","status":"COMPLETED","sponsor":"University of Washington","startDate":"2022-05-25","conditions":"HPV Infection, HPV Vaccination","enrollment":158},{"nctId":"NCT00513526","phase":"PHASE2","title":"Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Infection, Precancerous Condition","enrollment":112},{"nctId":"NCT00923702","phase":"PHASE4","title":"Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Partha Basu","startDate":"2009-09","conditions":"Cervical Cancer, Cervical Precancerous Lesions","enrollment":22729},{"nctId":"NCT05584332","phase":"PHASE3","title":"A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females","status":"TERMINATED","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2022-12-09","conditions":"Cervical Cancer, Genital Wart, CIN1","enrollment":3131},{"nctId":"NCT05838157","phase":"","title":"The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-05-04","conditions":"Menstrual Disorder, Premature Ovarian Failure","enrollment":600},{"nctId":"NCT03763565","phase":"","title":"Effectiveness of HPV Vaccine in Thai Adult Women","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2018-11-01","conditions":"Uterine Cervical Dysplasia, Papillomavirus Vaccines","enrollment":993},{"nctId":"NCT00380367","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05-03","conditions":"Papillomavirus Infections","enrollment":110},{"nctId":"NCT05761002","phase":"NA","title":"Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-06-01","conditions":"Human Papilloma Virus, Anogenital Wart","enrollment":58},{"nctId":"NCT05694728","phase":"PHASE2","title":"A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine","status":"COMPLETED","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2020-05-23","conditions":"Human Papilloma Virus Infection","enrollment":780},{"nctId":"NCT05668572","phase":"PHASE3","title":"A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine","status":"UNKNOWN","sponsor":"Beijing Health Guard Biotechnology, Inc","startDate":"2020-12-05","conditions":"Human Papillomavirus Infection","enrollment":12000},{"nctId":"NCT01914367","phase":"PHASE4","title":"Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2013-06-25","conditions":"Infection With Human Papillomavirus","enrollment":12},{"nctId":"NCT03998254","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-26","conditions":"Papillomavirus Infections","enrollment":6000},{"nctId":"NCT05173324","phase":"PHASE3","title":"Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2023-02-01","conditions":"HPV Infection","enrollment":8000},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT05383625","phase":"PHASE3","title":"Gardasil Versus Cervarix in the Treatment of Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-09-01","conditions":"Verruca Viral","enrollment":50},{"nctId":"NCT02009800","phase":"PHASE3","title":"ICI-VPH: Impact of HPV Immunisation Schedules Against HPV","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2013-11","conditions":"Human Papillomavirus Infections","enrollment":3364},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT02993757","phase":"PHASE3","title":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-12-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease","enrollment":528},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT04425291","phase":"PHASE3","title":"Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","status":"COMPLETED","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2020-05-28","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":1680},{"nctId":"NCT03465280","phase":"","title":"Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)","status":"UNKNOWN","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2018-04-01","conditions":"Recurrent Respiratory Papillomatosis, Human Papilloma Virus","enrollment":400},{"nctId":"NCT05149248","phase":"PHASE2, PHASE3","title":"Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2018-05-30","conditions":"Cancer of Cervix","enrollment":6000},{"nctId":"NCT00339040","phase":"PHASE2","title":"Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"HIV Infections, Sexually Transmitted Diseases","enrollment":130},{"nctId":"NCT00604175","phase":"PHASE2","title":"Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-02","conditions":"HIV Infections, Sexually Transmitted Diseases","enrollment":319},{"nctId":"NCT01461096","phase":"PHASE3","title":"Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-03","conditions":"HIV Infections","enrollment":575},{"nctId":"NCT05060484","phase":"PHASE2","title":"A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-10-19","conditions":"Interventional, Prevention, Randomized","enrollment":1800},{"nctId":"NCT01492582","phase":"PHASE2","title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-07","conditions":"Cancer Survivor, Prevention of Human Papillomavirus Infection","enrollment":1499},{"nctId":"NCT04453241","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety Study of NBP615 in Healthy Female","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2018-12-22","conditions":"Cervical Cancer","enrollment":200},{"nctId":"NCT04391647","phase":"","title":"Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2020-05-11","conditions":"Human Papilloma Virus Infection","enrollment":50},{"nctId":"NCT04921111","phase":"PHASE1","title":"A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2021-07-02","conditions":"HPV Infection Vaccine Safety SCT1000","enrollment":240},{"nctId":"NCT01432574","phase":"PHASE2","title":"Study of Gardasil in Mid-Adult Males (MAM)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-19","conditions":"Human Papillomavirus","enrollment":150},{"nctId":"NCT02968420","phase":"PHASE4","title":"Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-09-11","conditions":"Human Papillomavirus","enrollment":18},{"nctId":"NCT04920526","phase":"","title":"Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls","status":"UNKNOWN","sponsor":"Kenya Medical Research Institute","startDate":"2021-08","conditions":"HPV-Related Carcinoma","enrollment":135},{"nctId":"NCT02087384","phase":"PHASE4","title":"HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)","status":"COMPLETED","sponsor":"Prof. Jan Prins","startDate":"2014-03","conditions":"AIN, HIV","enrollment":126},{"nctId":"NCT02624349","phase":"PHASE4","title":"Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2013-10","conditions":"Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma","enrollment":37},{"nctId":"NCT04711265","phase":"","title":"Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2015-09","conditions":"HPV Vaccine, HPV Infection, HIV-1-infection","enrollment":176},{"nctId":"NCT01101750","phase":"PHASE4","title":"Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2010-05","conditions":"Cervical Cancer, Hpv, Warts","enrollment":25},{"nctId":"NCT02934724","phase":"","title":"Impact of HPV Vaccine On The Prevalence Of HPV In Norway","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-11","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer","enrollment":315},{"nctId":"NCT00956553","phase":"PHASE4","title":"Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls","status":"COMPLETED","sponsor":"Public Health England","startDate":"2009-09","conditions":"HPV Infections","enrollment":400},{"nctId":"NCT01209325","phase":"PHASE2","title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2011-06-28","conditions":"Anal Cancer, Nonneoplastic Condition, Penile Cancer","enrollment":149},{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT01031069","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-26","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":873},{"nctId":"NCT01928225","phase":"PHASE2","title":"Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-09-02","conditions":"Cervical High Grade Squamous Intraepithelial Lesion","enrollment":180},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT02576054","phase":"PHASE3","title":"Safety and Tolerability Study of V501 in Japanese Boys (V501-200)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-20","conditions":"Anogenital Human Papilloma Virus Infection, Condyloma Acuminata","enrollment":101},{"nctId":"NCT01462357","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-21","conditions":"Infections, Papillomavirus","enrollment":1079},{"nctId":"NCT04096911","phase":"PHASE2","title":"Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"Buhai Wang","startDate":"2019-07-31","conditions":"Uterine Cervical Neoplasms, Cervical Cancer, Cervical Neoplasms","enrollment":20},{"nctId":"NCT01092195","phase":"PHASE1","title":"Gardasil Vaccination in Post Stem Cell Transplant Patients","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-06-02","conditions":"Gardasil Vaccine, Stem Cell Transplant, Immunogenicity","enrollment":64},{"nctId":"NCT04022148","phase":"","title":"The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years","status":"UNKNOWN","sponsor":"University of Fukui","startDate":"2019-08-01","conditions":"Cancer of Cervix, Vaccinia","enrollment":2800},{"nctId":"NCT01446718","phase":"","title":"A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2014-12-15","conditions":"Human Papillomavirus, HIV-1 Infection","enrollment":179},{"nctId":"NCT02837926","phase":"PHASE4","title":"Comparing Health Services Interventions for the Prevention of HPV-related Cancer","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2016-05","conditions":"Cervical Cancer","enrollment":63},{"nctId":"NCT01862874","phase":"PHASE3","title":"Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-27","conditions":"Anogenital Human Papilloma Virus Infection, Condyloma Acuminata","enrollment":1124},{"nctId":"NCT00834106","phase":"PHASE3","title":"Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-31","conditions":"HPV Infections","enrollment":3006},{"nctId":"NCT01375868","phase":"PHASE3","title":"Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis","status":"COMPLETED","sponsor":"Ruth Tachezy, PhD.","startDate":"2011-10","conditions":"Squamous Papilloma of the Larynx","enrollment":51},{"nctId":"NCT01461993","phase":"PHASE2","title":"A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-28","conditions":"Vaccines, Meningococcal Vaccines","enrollment":2499},{"nctId":"NCT01304498","phase":"PHASE3","title":"Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-23","conditions":"Human Papillomavirus","enrollment":600},{"nctId":"NCT01544478","phase":"PHASE4","title":"V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-25","conditions":"Cervical Cancer, Cervical Intraepithelial Neoplasia, Adenocarcinoma in Situ","enrollment":1030},{"nctId":"NCT00543543","phase":"PHASE3","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-24","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":14840},{"nctId":"NCT01245764","phase":"PHASE3","title":"GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-21","conditions":"Papillomavirus Infections","enrollment":250},{"nctId":"NCT01741012","phase":"PHASE1","title":"Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2013-01","conditions":"Systemic Lupus Erythematosus","enrollment":37},{"nctId":"NCT02114385","phase":"PHASE3","title":"A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-24","conditions":"Papilloma Viral Infection","enrollment":500},{"nctId":"NCT03085381","phase":"PHASE1","title":"A Phase I Study of Quadrivalent HPV Recombinant Vaccine","status":"COMPLETED","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","startDate":"2016-12","conditions":"HPV Infections","enrollment":90},{"nctId":"NCT01717118","phase":"PHASE4","title":"Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2009-11","conditions":"Healthy","enrollment":2000},{"nctId":"NCT00090285","phase":"PHASE3","title":"An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-09-03","conditions":"Condylomata Acuminata","enrollment":4065},{"nctId":"NCT03083249","phase":"","title":"Gardasil Knowledge","status":"COMPLETED","sponsor":"Sarah Hostetter, MD","startDate":"2017-02-01","conditions":"HPV","enrollment":50},{"nctId":"NCT02196454","phase":"NA","title":"Video to Promote HPV Vaccination","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-07","conditions":"Vaccine Acceptance, Social Acceptance, Acceptance Processes","enrollment":110},{"nctId":"NCT01960088","phase":"","title":"Adolescent Vaccination in Pharmacies","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-07","conditions":"Evaluating Attitudes Toward HPV Vaccinations in Pharmacies, Evaluating the Provision of HPV Vaccines in a Pharmacy","enrollment":1509},{"nctId":"NCT03296397","phase":"PHASE3","title":"Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-11-15","conditions":"Genital Warts","enrollment":300},{"nctId":"NCT00092547","phase":"PHASE3","title":"A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-10-08","conditions":"Human, Papillomavirus Infections","enrollment":1781},{"nctId":"NCT00786409","phase":"NA","title":"Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2008-11","conditions":"Systemic Lupus Erythematosus","enrollment":27},{"nctId":"NCT03431246","phase":"PHASE3","title":"Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-10-01","conditions":"Human Papillomavirus Vaccines","enrollment":32},{"nctId":"NCT02714114","phase":"","title":"Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-09","conditions":"Human Papilloma Virus Infection","enrollment":57},{"nctId":"NCT00090220","phase":"PHASE3","title":"A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-16","conditions":"Healthy Adult Female Participants, Prevention, Papillomavirus Infection","enrollment":3819},{"nctId":"NCT00411749","phase":"PHASE2","title":"V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"HPV Infections","enrollment":107}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABORTION SPONTANEOUS"}],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gardasil"],"phase":"marketed","status":"active","brandName":"quadrivalent human papillomavirus vaccine","genericName":"quadrivalent human papillomavirus vaccine","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Biologic","firstApprovalDate":"","aiSummary":"The vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18) to prevent infection and associated diseases. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}